Drugs / [18F]RO6958948
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02792179 | Jul → Sep 2016 | Alzheimer disease | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 1 | NCT02187627 | Aug 2014 → Feb 2016 | Alzheimer disease 5 | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [18F]RO6958948 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02187627 ↗ |
| Modality | Diagnostic / imaging agent | “three PET imaging tracers developed to detect tau pathology in the brain” NCT02187627 ↗ |
| Route | Intravenous | “administered as single intravenous injection” NCT02187627 ↗ |